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Severe fever with thrombocytopenia syndrome (SFTS) is an 
emerging infectious zoonosis caused by the SFTS virus (SFTSV), 
a newly identified Phlebovirus in the family Phenuiviridae car-
ried by Haemaphysalis longicornis ticks.1 It is an endemic dis-
ease in China, South Korea, and Japan,2 with a case fatality 
rate of 16.2% to 30%.3,4 Hemophagocytic lymphohistiocytosis 
(HLH) is an immune-mediated life-threatening syndrome as-
sociated with excessive immune activation.5 Hyperferritinemia 
has been identified as a surrogate marker for both HLH and 
SFTS.6 The major source of high ferritin in HLH has been sug-
gested as a result of activated macrophages in the bone mar-
row or spleen.7 Cytokine storms in SFTS cause disease progres-
sion resulting in a more severe form of clinical severity.8 For 
this reason, the association of HLH features in SFTS patients 
has been suggested as a critical factor attributable to increased 
risk of mortality.9 Fatal cases of SFTS associated with HLH 
have been described by previous studies,4,5,9 although most are 
brief reports of one or two cases. The aim of this study was to 
demonstrate the clinical features and outcomes of SFTS patients 
complicated by HLH and to compare the frequency of HLH-
criteria factors according to outcomes.
This was a retrospective cohort study based on patients 
treated for SFTS at a tertiary health care hospital in Wonju, 
South Korea from October 2015 to August 2017. Blood sam-
ples obtained from patients during the acute phase of illness 
were referred to the Korea Centers for Disease Control and 
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Prevention for confirmation of SFTSV infection. Using a viral 
RNA extraction kit (iNtRON Biotechnology, Seongnam, Ko-
rea), RNA was extracted from the serum of the patients. For 
detection of SFTSV RNA, reverse transcription (RT)-PCR was 
performed using a DiaStar 2X OneStep RT-PCR Pre-Mix kit 
(SolGent, Daejeon, Korea) under the following conditions ac-
cording to the manufacturer’s instructions: an initial step of 
30 min at 50°C for RT and 5 min at 95°C for denaturation; 35 
cycles of 20 s at 95°C, 40 s at 58°C, and 30 s at 72°C; and a final 
extension step of 5 min at 72°C. Primers MF3 (5'-GATGAGATG 
GTC-CATGCTGATTCT-3') and MR2 (5'-CTCATGGGGTG-
GAATGTCCTCAC-3') were used.10 
Cases presenting with five or more clinical or laboratory find-
ings corresponding to the HLH-2004 diagnostic criteria were 
defined as SFTS cases complicated by HLH.11 The criteria used 
in the HLH-2004 trial are as follows: fever ≥38.5°C, splenomeg-
aly, peripheral blood cytopenia, hypertriglyceridemia (fasting 
triglycerides >265 mg/dL) and/or hypofibrinogenemia (fibrin-
ogen <150 mg/dL), hemophagocytosis, serum ferritin >500 
ng/mL, elevated soluble CD25 (soluble interleukin-2 receptor 
alpha chain) two SDs above age-adjusted laboratory-specific 
norms, and low or absent natural killer (NK) cell activity. Cy-
topenia was defined as at least two affected cell lineages: he-
moglobin <9 g/dL (reference 12–16 g/dL), platelets <100000/
microL (reference 150000–450000/microL), absolute neutro-
phil count <1000/microL (reference 1800–7500/microL). 
Presence of hemophagocytosis was confirmed when identi-
fied in bone marrow, spleen, lymph node, or liver.11 Cardio-
vascular disease was defined in patients with established cor-
onary artery disease, ischemic stroke, transient ischemic 
attack, or peripheral arterial disease.12 Diabetes was defined 
as documentation of two consecutive fasting blood glucose 
measurements ≥7 mmol/L or HbA1c ≥6.5%. Liver disease was 
defined in patients with chronic liver disease due to viral or al-
coholic cause. Renal disease was defined in patients with chron-
ic kidney disease according to the Kidney Disease Improving 
Global Outcomes guidelines.13
Analysis of the frequency of each criterion was conducted. 
Case-fatality proportions for each criterion were compared. 
Descriptive statistic procedures were performed to analyze 
the cases. Categorical variables are presented as numbers and 
percentages. Continuous variables are presented as a median, 
interquartile range. Dichotomous variables were analyzed us-
ing Fisher’s exact test. Continuous variables were analysed us-
ing the Mann Whitney U-test. Statistical analyses were per-
formed using SPSS version 23 (IBM Corp., Armonk, NY, USA). 
p values <0.05 were considered statistically significant. The 
study was approved by the Institutional Ethics Committee of 
Wonju Severance Christian Hospital (approval No. CR318141). 
Informed consent was waived by the board.
During the study period, 18 patients were confirmed and 
treated for SFTS. The clinical and laboratory characteristics of 
the 18 patients at the time of admission are presented in Table 1. 
Nine (50%) of the patients were male, with a median age of 
74 years. Males had higher non-fatality proportions of 57.1% 
(8/14). The presence of a tick bite wound on physical examina-
tion was confirmed in 12 (66.7%) patients. Meningoencephali-
tis with altered mental status as the initial presenting symptom 
was seen in 4 (22.2%) patients. Ventilator care was required in 
3 (16.7%) patients, and 1 (5.6%) patient experienced a tachyar-
rhythmia event and bleeding during hospitalization. Two 
(11.1%) patients suffered with acute renal failure requiring 
hemodialysis. For treatment, 6 (33.3%) patients received plas-
ma exchange for three days. Ribavirin, interferon, and intrave-
nous immunoglobulin was administered in 8 (44.4%), 4 
(22.2%), and 3 (16.7%) patients, respectively. Cyclosporine 
and etoposide (VP-16) was administered in 1 (5.6%) patient 
each.
In this study, a case-fatality proportion of 22.2% [4 among 
18 cases, 95% confidence interval (CI) 9%–45.2%] was record-
ed. SFTS cases complicated by HLH were identified in 33.3% 
(6 among 18 cases, 95% CI 16.3%–56.3%). The frequencies of 
hemophagocytosis [5/14 (35.7%) vs. 4/4 (100%), p=0.082], cy-
topenia [12/14 (85.7%) vs. 4/4 (100%), p=1.000], hypertriglyc-
eridemia [9/14 (64.3%) vs. 4/4 (100%), p=1.000], and hyperfer-
ritinemia [10/14 (83.3%) vs. 4/4 (100%), p=1.000] did not differ 
significantly between fatal and non-fatal cases. A mortality rate 
of 75% (3 among 4 cases) was recorded among SFTS cases 
complicated by HLH. Although there was no statistically signifi-
cant differences in outcomes, fatal cases demonstrated more 
frequent correlation to the HLH-2004 criteria, compared to non-
fatal cases [3/14 (21.4%) vs. 3/4 (75.0%), p=0.083]. 
Table 2 lists the clinical characteristics, laboratory data, and 
outcomes of the six cases with five or more factors correspond-
ing to the HLH-2004 diagnostic criteria. With the exception of 
case number 2, all cases were identified with thrombocytope-
nia on initial laboratory results. Leukopenia, hyperferritinemia, 
and hemophagocytosis in the bone marrow (Fig. 1) were iden-
tified in all six cases. One fatal case was complicated by me-
ningoencephalitis. Despite aggressive ventilator care, plasma-
pheresis and ribavirin administration, case number 5 resulted 
in death. Case number 4 survived after receiving plasmapher-
esis and ribavirin, and case number 6 who also survived was 
treated with plasmapheresis only.
SFTS is an endemic disease in rural South Korea, with a re-
ported incidence of 0.54 cases/10000 person-years from 2013 
to 2015 in the Gangwon area of South Korea.14 Although one 
multicenter study conducted in South Korea suggested that 
early plasma exchange may have a beneficial effect on the clinical 
outcomes of SFTS patients,15 there are no specific established 
treatments for SFTS.
Recent results from the Chinese national surveillance sys-
tem reported a case-fatality rate of 16.2% (95% CI 14.6–17.8).3 
The case-fatality rate was 22.2% in our study, higher than re-
ports from China. This discrepancy may be attributable to the 
underestimation of deaths of patients who had stopped thera-
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py, been discharged from the hospital, and died soon after re-
turning home. Moreover, older median age and a higher fre-
quency of comorbid underlying diseases may explain the higher 
rates of case-fatality reported in this study. 
Secondary HLH has been shown to be associated with SFTS 
with hyperferritinemia and evidence of hemophagocytosis in 
the bone marrow.16,17 In one study conducted in Japan, hemo-
phagocytosis in bone marrow was identified in 83% of cases, 
with a case-fatality proportion of 31%.16 In this study, hemo-
phagocytosis was identified in all four fatal cases. However, 
there were no statistically significant differences between fatal 
and non-fatal cases according to the presence of hemophago-
cytosis.
There are several limitations to our study. First, the study was 
limited by its retrospective nature and its small sample size. This 
was a single-center study, and although the center in which the 
study was conducted was located in a rural area of South Korea 
with a relatively high incidence of SFTS, only a limited number 
of cases were identifiable. Second, NK cell activity or soluble 
CD25 concentrations were not identifiable due to limitation of 
Table 1. Baseline Characteristics of the 18 SFTS Confirmed Cases
Characteristics Total (n=18) Survival (n=14) Mortality (n=4) p value
Gender, male 9 (50.0) 8 (57.1) 1 (25.0) 0.576*
Age, median year (IQR) 74 (66, 77) 72 (66, 77) 76 (62, 83) 0.534†
Hospital days (IQR) 12 (6, 17) 12 (6, 18) 10 (5, 15) 0.464†
Confirmed insect bite 12 (66.7) 10 (71.4) 2 (50.0) 0.569*
Underlying comorbidities
Diabetes mellitus 4 (22.2) 3 (21.4) 1 (25.0) 1.000*
Cardiovascular 7 (38.9) 4 (28.6) 3 (75.0) 0.245*
Liver disease 2 (11.1) 1 (7.1) 1 (25.0) 0.405*
Renal disease 1 (5.6) 1 (7.1) 0 (0) 1.000*
Solid organ cancer 2 (11.1) 2 (14.3) 0 (0) 1.000*
Complication
Meningoencephalitis 4 (22.2) 3 (21.4) 1 (25.0) 1.000*
Ventilator care 3 (16.7) 1 (7.1) 2 (50.0) 0.108*
Arrhythmia 1 (5.6) 1 (7.1) 0 (0) 1.000*
Bleeding 1 (5.6) 2 (11.1) 1 (25.0) 0.222*
Hemodialysis 2 (11.1) 2 (14.3) 0 (0) 1.000*
Treatment
Plasmapheresis 6 (33.3) 4 (28.6) 2 (50.0) 0.569*
Ribavirin 8 (44.4) 6 (42.9) 2 (50.0) 1.000*
Interferon 4 (22.2) 2 (14.3) 2 (50.0) 0.197*
IVIG 3 (16.7) 2 (14.3) 1 (25.0) 1.000*
Cyclosporine 1 (5.6) 0 (0) 1 (25.0) 0.222*
Etoposide (VP-16) 1 (5.6) 0 (0) 1 (25.0) 0.222*
Available laboratory test results
CBC 18 (100) 14 (100) 4 (100)
Triglyceride 18 (100) 14 (100) 4 (100)
Ferritin 16 (88.9) 12 (85.7) 4 (100) 1.000*
Bone marrow examination 9 (50.0) 5 (35.7) 4 (100) 0.082*
The HLH-2004 criteria
Fever 18 (100) 14 (100) 4 (100)
Splenomegaly 0 (0) 0 (0) 0 (0)
Hemophagocytosis 9 (50.0) 5 (35.7) 4 (100) 0.082*
Cytopenia 16 (88.9) 12 (85.7) 4 (100) 1.000*
Hypertriglyceridemia 12 (66.7) 9 (64.3) 3 (75.0) 1.000*
Hyperferritinemia 14 (87.5) 10 (83.3) 4 (100) 1.000*
No. cases with five or more factors corresponding to 2004-HLH criteria 6 (33.3) 3 (21.4) 3 (75.0) 0.083*
IVIG, intravenous immunoglobulin; HLH, hemophagocytic lymphohistiocytosis; SFTS, severe fever with thrombocytopenia syndrome; CBC, complete blood count; 
IQR, interquartile range.
The data were expressed as the number of patients (%) or median (IQR).
*Fisher’s exact test was performed, †Mann-Whitney U-test was performed.
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laboratory resources. Moreover, serum ferritin and bone mar-
row examination was not performed for all cases. This may have 
caused an underestimation in diagnosis of HLH complicated 
cases. 
Although there were no statistically significant differences 
in outcomes between HLH complicated cases and HLH non-
complicated cases, 75% mortality was identified in SFTS cases 
complicated by HLH. Although further studies with a larger 
number of patients are needed to support this finding, the pres-
ent study suggests the possibility that SFTS cases complicated 
by HLH are at higher risk of poor prognosis. 
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